Molecular pathology of malignant melanoma: Changing the clinical practice paradigm toward a personalized approach

Joshua R. Bradish, Liang Cheng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Melanocytic proliferations are notoriously difficult lesions to evaluate histologically, even among experts, as there is a lack of objective, highly reproducible criteria, which can be broadly applied to the wide range of melanocytic lesions encountered in daily practice. These difficult diagnoses are undeniably further compounded by the substantial medicolegal risks of an "erroneous" diagnosis. Molecular information and classification of melanocytic lesions is already vast and constantly expanding. The application of molecular techniques for the diagnosis of benignity or malignancy is, at times, confusing and limits its utility if not used properly. In addition, current and future therapies will necessitate molecular classification of melanoma into one of several distinct subtypes for appropriate patient-specific therapy. An understanding of what different molecular markers can and cannot predict is of the utmost importance. We discuss both mutational analysis and chromosomal gains/losses to help clarify this continually developing and confusing facet of pathology.

Original languageEnglish
Pages (from-to)1315-1326
Number of pages12
JournalHuman Pathology
Volume45
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Molecular Pathology
Melanoma
Pathology
Therapeutics
Neoplasms

Keywords

  • BRAF mutation
  • KIT mutation
  • Malignant melanoma
  • Molecular genetics
  • Molecular pathology
  • Personalized medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular pathology of malignant melanoma : Changing the clinical practice paradigm toward a personalized approach. / Bradish, Joshua R.; Cheng, Liang.

In: Human Pathology, Vol. 45, No. 7, 2014, p. 1315-1326.

Research output: Contribution to journalArticle

@article{4f9c5888c6ee4d018300c6bb699c3095,
title = "Molecular pathology of malignant melanoma: Changing the clinical practice paradigm toward a personalized approach",
abstract = "Melanocytic proliferations are notoriously difficult lesions to evaluate histologically, even among experts, as there is a lack of objective, highly reproducible criteria, which can be broadly applied to the wide range of melanocytic lesions encountered in daily practice. These difficult diagnoses are undeniably further compounded by the substantial medicolegal risks of an {"}erroneous{"} diagnosis. Molecular information and classification of melanocytic lesions is already vast and constantly expanding. The application of molecular techniques for the diagnosis of benignity or malignancy is, at times, confusing and limits its utility if not used properly. In addition, current and future therapies will necessitate molecular classification of melanoma into one of several distinct subtypes for appropriate patient-specific therapy. An understanding of what different molecular markers can and cannot predict is of the utmost importance. We discuss both mutational analysis and chromosomal gains/losses to help clarify this continually developing and confusing facet of pathology.",
keywords = "BRAF mutation, KIT mutation, Malignant melanoma, Molecular genetics, Molecular pathology, Personalized medicine, Targeted therapy",
author = "Bradish, {Joshua R.} and Liang Cheng",
year = "2014",
doi = "10.1016/j.humpath.2014.04.001",
language = "English",
volume = "45",
pages = "1315--1326",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Molecular pathology of malignant melanoma

T2 - Changing the clinical practice paradigm toward a personalized approach

AU - Bradish, Joshua R.

AU - Cheng, Liang

PY - 2014

Y1 - 2014

N2 - Melanocytic proliferations are notoriously difficult lesions to evaluate histologically, even among experts, as there is a lack of objective, highly reproducible criteria, which can be broadly applied to the wide range of melanocytic lesions encountered in daily practice. These difficult diagnoses are undeniably further compounded by the substantial medicolegal risks of an "erroneous" diagnosis. Molecular information and classification of melanocytic lesions is already vast and constantly expanding. The application of molecular techniques for the diagnosis of benignity or malignancy is, at times, confusing and limits its utility if not used properly. In addition, current and future therapies will necessitate molecular classification of melanoma into one of several distinct subtypes for appropriate patient-specific therapy. An understanding of what different molecular markers can and cannot predict is of the utmost importance. We discuss both mutational analysis and chromosomal gains/losses to help clarify this continually developing and confusing facet of pathology.

AB - Melanocytic proliferations are notoriously difficult lesions to evaluate histologically, even among experts, as there is a lack of objective, highly reproducible criteria, which can be broadly applied to the wide range of melanocytic lesions encountered in daily practice. These difficult diagnoses are undeniably further compounded by the substantial medicolegal risks of an "erroneous" diagnosis. Molecular information and classification of melanocytic lesions is already vast and constantly expanding. The application of molecular techniques for the diagnosis of benignity or malignancy is, at times, confusing and limits its utility if not used properly. In addition, current and future therapies will necessitate molecular classification of melanoma into one of several distinct subtypes for appropriate patient-specific therapy. An understanding of what different molecular markers can and cannot predict is of the utmost importance. We discuss both mutational analysis and chromosomal gains/losses to help clarify this continually developing and confusing facet of pathology.

KW - BRAF mutation

KW - KIT mutation

KW - Malignant melanoma

KW - Molecular genetics

KW - Molecular pathology

KW - Personalized medicine

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84903121911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903121911&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2014.04.001

DO - 10.1016/j.humpath.2014.04.001

M3 - Article

C2 - 24856851

AN - SCOPUS:84903121911

VL - 45

SP - 1315

EP - 1326

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 7

ER -